Scholarly article on topic 'Familial Focal Congenital Hyperinsulinism'

Familial Focal Congenital Hyperinsulinism Academic research paper on "Clinical medicine"

Share paper
OECD Field of science

Academic research paper on topic "Familial Focal Congenital Hyperinsulinism"


Clinical Case Seminar

Familial Focal Congenital Hyperinsulinism

Dunia Ismail, Virpi V. Smith, Pascale de Lonlay, Maria-Joao Ribeiro, Jacques Rahier, Oliver Blankenstein, Sarah E. Flanagan, Christine Bellanne-Chantelot, Virginie Verkarre, Yves Aigrain, Agostino Pierro, Sian Ellard, and Khalid Hussain

Departments of Endocrinology, Histopathology, and Surgery (D.I., V.V.S., A.P., K.H.), Great Ormond Street Hospital for Children, National Health Service Trust, and The Institute of Child Health, University College London, London WC1N 1EH, United Kingdom; Department of Pediatrics (P.d.L., M.-J.R., V.V., Y.A.), Hôpital Necker Enfants Malades, Université Paris-Descartes, Faculte de Médecine Paris Descarte, 75743 Paris, France; Department of Pathology (J.R.), Cliniques Universitaires St. Luc, Université catholique de Louvain, 1200 Brussels, Belgium; Department of Pediatrics (O.B.), Humboldt-Universitat zu Berlin, and Charite Kinderklinik, Berlin 10115, Germany; Institute of Biomedical and Clinical Science (S.E.F., S.E.), Peninsula Medical School, University of Exeter, Exeter EX2 5DW, United Kingdom; and Department of Genetics (C.B.-C.), Hospital La Pitie Salpetriere, 75743 Paris, France

Background: Congenital hyperinsulinism (CHI) is a cause of persistent hypoglycemia. Histologically, there aretwo subgroups, diffuse and focal. Focal CHI is a consequence of two independent events, inheritance of a paternal mutation in ABCC8/KCNJ11 and paternal uniparental isodisomy of chromosome 11p15 within the embryonic pancreas, leading to an imbalance in the expression of imprinted genes. The probability of both events occurring within siblings is rare.

Aim: We describe the first familial form of focal CHI in two siblings.

Patients and Methods: The proband presented with medically unresponsive CHI. He underwent pancreatic venous sampling and Fluorine-18-L-dihydroxyphenylalanine positron emission tomography scan, which localized a 5-mm focal lesion in the isthmus of the pancreas. The sibling presented 8 yr later also with medically unresponsive CHI. An Fluorine-18-L-dihydroxyphenylalanine positron emission-computerised tomography scan showed a 7-mm focal lesion in the posterior section of the head of the pancreas. Both siblings were found to be heterozygous fortwo paternally inherited ABCC8 mutations, A355T and R1494W. Surgical removal of the focal lesions in both siblings cured the Hyperinsulinaemic hypoglycaemia.

Conclusion: This isthe first report of focal CHI occurring in siblings. Genetic counseling forfamilies of patients with focal CHI should be recommended, despite the rare risk of recurrence of this disease. (J Clin Endocrinol Metab 96: 24-28, 2011)

Congenital hyperinsulinism (CHI) is a cause of severe hypoglycemia due to unregulated insulin secretion. Histologically, there are two major subgroups of CHI, diffuse and focal (1, 2), that are unrelated to nesidioblastosis (3). In diffuse CHI, there is an abnormality in all pancreatic ^-cells throughout the pancreas. In focal CHI, the abnormality is confined to a small region of the pancreas (focal adenomatous hyperplasia). Diffuse CHI is

ISSN Print 0021-972X ISSN Online 1945-7197 Printed in U.S.A.

Copyright © 2011 by The Endocrine Society

doi: 10.1210/jc.2010-1524 Received July 2, 2010. Accepted September 13, 2010. First Published Online October 13, 2010

commonly due to recessive mutations in ABCC8/KCNJ11 (encoding for the SUR1 and Kir6.2 protein on the pancreatic ^-cell KATP channel, respectively). Focal CHI is caused by the combination of a paternally inherited heterozygous germ line mutation in ABCC8/KCNJ11 and somatic paternal uniparental isodisomy (UPD) for chromosome 11p15.5 within a pancreatic progenitor cell (4, 5). The loss of the maternal 11p15.5 region leads to an

Abbreviations: CHI, Congenital hyperinsulinism; 18F-DOPA-PET, Fluorine-18-L-dihydroxy-phenylalanine positron emission tomography; 18F-DOPA-PET-CT, Fluorine-18-L-dihy-droxyphenylalanine positron emission-computerised tomography; PVS, portal venous sampling; UPD, uniparental isodisomy.

24 J Clin Endocrinol Metab, January 201 1, 96(1):24-28

imbalance in the expression of imprinted genes within this region and a growth advantage for the cell that ultimately becomes the focal lesion. The hyperinsulin-ism results from the paternally inherited ABCC8/ KCNJ11 mutation, which is homozygous within the focal lesion due to loss of the maternal allele. Preoper-ative localization of the focal form with Fluorine-18-L-dihydroxyphenylalanine positron emission-computerised tomography (18F-DOPA-PET-CT) scan and removal of the focal lesion provides cure for the patient.

The most common region of UPD on chromosome 11 encompasses two areas of interest, the 11p15.5 region (which is imprinted) and the 11p15.1 region (not imprinted), which contains the genes ABCC8/KCNJ11 (6, 7). The 11p15.5 region contains several imprinted genes characterized by monoallelic expression. These include maternally expressed genes such as H19 (a candidate tumor suppressor gene) and CDKN1C (a negative regulator of cell proliferation and paternally expressed genes such as the IGF2). CDKN1C (p57KIP2) encodes for the p57 protein, which is absent in focal CHI by immunohistochem-istry (8). The imbalance between imprinted genes (increased IGF2 and diminished H19 and CDKN1C) gives rise to the increase in proliferation of ^-cells.

The probability of a sibling of a child with focal CHI inheriting the paternal ABCC8/KCNJ11 mutation is 50%, but the likelihood of the second sibling also having

somatic paternal UPD for chromosome 11p15.5 is very rare, and so far no siblings with focal forms of CHI have been described. We now describe the first familial form of focal CHI.

Subjects and Methods

Clinical history Index case

The first sibling was born at term with a birth weight of 3.76 kg. At 8 h of age, he was noticed to be cyanosed, and investigations confirmed hyperinsulinism (blood glucose, 1.9 mmol/liter; simultaneous serum insulin, 32.4 mU/liter). He failed to respond to diazoxide (20mg/kg • d) and octreotide. Transhepatic hepatic portal venous sampling (PVS) was performed (9) as well as an 18F-DOPA-PET. PVS showed a focal lesion in the isthmus of the pancreas, and the 18F-DOPA-PET scan also showed increased uptake in the region of the isthmus (Fig. 1, A and B). At operation, a focal lesion was found in the position suggested by the PVS and the 18F-DOPA-PET scan and was removed. After removal of the focal lesion, the child was cured with no more episodes of hypoglycemia.

Clinical history of sibling

The sibling was born 8 yr after the index case first presented. She was born at term with a weight of 4.2 kg. She presented soon after birth symptoms of lethargy and poor feeding. A blood glucose concentration of 0.5 mmol/liter was documented with a

FIG. 1. A, Pancreatic venous sampling. B, 18F-DOPA-PET [with magnetic resonance imaging (MRI)] scan for the index case. Both the pancreatic venous sampling and the 18F-DOPA-PET scan show the focal lesion to be located in the isthmus region of the pancreas (arrow). C, 18F-DOPA-PET-CT scan of the sibling. The standard uptake value (SUV) was highest in the head of the pancreas.

simultaneous serum insulin level of 10 mU/liter. She failed to respond to 20 mg/kg • d of diazoxide and octreotide. An 18F-DOPA-PET-CT scan showed a focal lesion superiorly located in the posterior section of the head of the pancreas (measuring 5 X 4 X 7 mm; Fig. 1C), although intraoperatively the lesion was more inferior. The pancreatic head was excised, and then a distal pancreatico-jejunostomy was performed. There were no postoperative complications, and the child was normoglycemic.


This study was approved by the Ethics Committee of Great Ormond Street Children's Hospital and the Institute of Child Health.


Intraoperative frozen section diagnosis was done on hematoxylin and eosin (and toluidine blue) stained frozen sections, after which the specimens were fixed in buffered formalin and processed into paraffin wax. Paraffin sections from the lesion were immunostained as previously described (10).


Genomic DNA was extracted from peripheral leukocytes. The 39 exons of the ABCC8 gene were amplified in the female sibling by the PCR (PCR primer sequences are available on request). Unidirectional sequencing was performed using universal M13 primers and a Big Dye Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, Warrington, UK) according to manufacturer's instructions. Reactions were analyzed on an ABI 3730 Capillary sequencer (Applied Biosystems), and sequences were compared with the reference sequences (NM_000525 and NM_000352.2) using Mutation Surveyor v3.24 (SoftGenetics, State College, PA). Mutation testing was undertaken for the affected brother and unaffected parents.

Loss of heterozygosity was investigated in the female sibling by microsatellite analysis of DNA extracted from paraffin-embedded pancreatic tissue and peripheral leukocytes. Six markers (D11S2071, D11S1964, D11S419, D11S1397, D11S1888, and D114138) were amplified by PCR, and allele peak heights were compared using GeneMarker v1.85 (SoftGenetics). Primer sequences are available on request.



In the index case, a small focal lesion (5 mm of large axis) was found at the junction of the corpus and the tail of the pancreas. It was characterized by nodular hyperplasia of islet-like cell clusters, including ductuloinsular complexes and scattered giant ^-cell nuclei (characteristic of focal adenomatous hyperplasia; Fig. 2B). Outside the focal lesion, the islets were small, with reduced cytoplasm and crowded nuclei (Fig. 2A). p57KIP2 was expressed in these resting islets but not in the endocrine tissue from the focal lesion, demonstrating a loss of heterozygosity of the 11p15 region. Because the lesion was small, no lesional tissue was available in the paraffin block to perform mi-

FIG. 2. Intraoperative frozen section of index case stained by toluidine blue with normal pancreatic parenchyma with resting islet outside the lesion (X200) (A), and focal adenomatous hyperplasia composed of enlarged and coalescent islets with enlarged endocrine nuclei (X200) (B). The arrows point to the enlarged endocrine nuclei. C, Hematoxylin and eosin stain of focal lesion from sibling, also showing focal adenomatous hyperplasia with enlarged endocrine nuclei (X200) as shown with the arrows.

crosatellite marker analysis. In the sibling, a focal lesion (measuring 7 mm) was found in the inferior section of the head of the pancreas with histological features typical of focal adenomatous hyperplasia (Fig. 2C).


ABCC8 sequencing analysis identified two heterozygous mutations, A355T (c.1063G>A) and R1494W (c.4480C>T). The R1494W mutation is a loss of function mutation that has been identified in at least six unrelated probands with CHI to date (11). In contrast, the A355T mutation is novel, and although it affects a residue that is well conserved across species, its pathogenicity is currently uncertain. Family member testing demonstrated that the two ABCC8 mutations were in cis, with both affected siblings having inherited the two mutations from their unaffected father. An ABCC8 mutation of maternal origin was not identified.

Analysis of microsatellite markers across the chromosome 11p15.1-11p15.5 region showed loss of heterozygosity of the maternal allele in DNA extracted from the focal lesion when compared with leukocyte DNA for the female sibling. The heterozygous germ line mutations (A355T; R1494W) are therefore likely to be homozygous within the focal lesion.


This is the first report of focal CHI occurring in two siblings. In both siblings, the focal lesions were relatively

small (5 and 7 mm in the widest diameter). In the index case, the lesion was located in the isthmus, whereas in the sibling the lesion was located inferiorly in the head of the pancreas. The focal lesions were completely resected in both patients, providing complete cure from the hyperinsulinaemic hypoglycaemia. Using microsatellite markers in the second sibling, we were able to demonstrate loss of heterozygosity for maternal 11p15.1-11p15.5, which is the typical feature of focal lesions. In the index case, the loss of maternal heterozygosity was shown by the lack of p57kip2 using immunohistochemistry.

Both siblings inherited two heterozygous mutations in ABCC8, A355T (c.1063G>A) and R1494W (c.4480C>T). These mutations were both inherited from their unaffected father and therefore are in cis. The R1494W mutation is a loss of function mutation that has been identified in at least six unrelated probands with CHI to date (11). In contrast, the A355T mutation is novel, and although it affects a residue that is well conserved across species, its pathogenicity is currently uncertain. Thus, it is very likely that one or both of these mutations is pathogenic and the cause of the CHI.

The somatic loss of maternal heterozygosity resulting from paternal UPD of 11p15 is a rare event occurring during fetal development. In one series of 31 patients (7) and in another study looking at 56 pancreatectomy specimens (12), no families or siblings with focal CHI were described. The maternal loss of heterozygosity occurs during a narrow time frame in fetal pancreatic development. The timing of the loss of maternal heterozygosity determines the relative size of the focal lesion (7). Because the lesions were small in our patients, this indicates that the maternal heterozygosity for 11p15 event occurred late and involved few pancreatic lobules. If maternal heterozygos-ity for 11p15 event occurs early in pancreatic development, then this usually leads to large focal lesions (13).

The location of the focal lesions was different in both siblings (isthmus and head of pancreas). During development, the pancreas originates from two buds on the dorsal and the ventral side of the duodenum (14). The dorsal bud develops about 26 d after conception, and the ventral bud develops a few days later (15). The dorsal pancreatic bud gives rise to the superior half of the head, body, and tail of the pancreas, whereas the ventral pancreatic bud gives rise to the inferior half of the head and the un-cinate process. In the index case, the focal lesion was located in the region between the body and tail of the pancreas, whereas in the sibling the focal lesion was located in the posterior section of the head of the pancreas. Thus, this suggests that the somatic 11p15.5 UPD events probably occurred in the dorsal and ventral buds of the male and female siblings, respectively.

The paternally inherited ABCC8 mutation and the somatic paternal UPD for 11p15 occurring in the pancreatic |-cell are two independent genetic events. Germline mutations in ABCC8 are not expected to increase the risk of the somatic event occurring unless by chance only. The frequency of CHI in outbred communities is about 1 in 40,000 to 1 in 50,000. This equates to about 1 in 90,000 focal cases and 1 in 90,000 diffuse cases. Because the carrier frequency is around 1 in 150 and because the number of focal cases is roughly the same as diffuse cases, the risk of paternal UPD occurring in a cell within the embryonic pancreas is around 1 in 600. The chance of one sibling being affected with focal CHI is 1 in 90,000. For the second sibling, the risk of inheriting the paternal mutation is 1 in 2, and the risk of paternal UPD is 1 in 600. Hence, the recurrence risk for future siblings of a child with focal CHI is 1 in 1200.

In conclusion, this is the first report of focal CHI in siblings, and it suggests that focal CHI can occur in siblings. We would recommend genetic counseling for families of patients with focal CHI, despite the very rare risk of recurrence of this disease.


Address all correspondence and requests for reprints to: Dr. K. Hussain, Clinical and Molecular Genetics Unit, Developmental Endocrinology Research Group, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, United Kingdom. E-mail:

This work was supported by the Wellcome Trust (Project Grant no. WT081188AIA).

Disclosure Summary: There is no conflict of interest for any of the authors.


1. Goossens A, Gepts W, SaudubrayJM, BonnefontJP, Nihoul-Fekete C, Heitz PU, Kloppel G 1989 Diffuse and focal nesidioblastosis. A clinicopathological study of 24 patients with persistent neonatal hyperinsulinemic hypoglycemia. Am J Surg Pathol 13:766-775

2. Kloppel G, Reinecke-LUthge A, Koschoreck F 1999 Focal and diffuse |8-cell changes in persistent hyperinsulinemic hypoglycemia of infancy. Endocr Pathol 10:299-304

3. Rahier J, Guiot Y, Sempoux C 2000 Persistent hyperinsulinaemic hypoglycaemia of infancy: a heterogeneous syndrome unrelated to nesidioblastosis. Arch Dis Child Fetal Neonatal Ed 82:F108-F112

4. Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C 1998 Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest 102:1286-1291

5. de Lonlay P, Fournet JC, Rahier J, Gross-Morand MS, Poggi-Travert F, Foussier V, Bonnefont JP, Brusset MC, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, JunienC 1997 Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsuline-

mic is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 100:802-807

6. Damaj L, le Lorch M, Verkarre V, Werl C, Hubert L, Nihoul-Fékété C, Aigrain Y, de Keyzer Y, Romana SP, Bellanne-Chantelot C, de Lonlay P,JaubertF 2008 Chromosome 11p15 paternal isodisomy in focal forms of neonatal hyperinsulinism. J Clin Endocrinol Metab 93:4941-4947

7. Fournet JC, Mayaud C, de Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM,JunienC 2001 Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. Am J Pathol 158:2177-2184

8. Kassem SA, Ariel I, Thornton PS, Hussain K, Smith V, Lindley KJ, Aynsley-Green A, Glaser B 2001 p57(KIP2) expression in normal islet cells and in hyperinsulinism of infancy. Diabetes 50:2763-2769

9. de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, Sempoux C, Vici CD, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fekete C, Robert JJ, Saudubray JM 1999 Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 340:1169-1175

10. Hussain K, Cosgrove KE, Shepherd RM, Luharia A, Smith VV, Kassem S, Gregory JW, Sivaprasadarao A, Christesen HT, Jacobsen BB, Brusgaard K, Glaser B, Maher EA, Lindley KJ, Hindmarsh P, Dattani M, Dunne MJ 2005 Hyperinsulinemic hypoglycemia in

Beckwith-Wiedemann syndrome due to defects in the function of pancreatic | -cell adenosine triphosphate-sensitive potassium channels. J Clin Endocrinol Metab 90:4376-4382

11. Flanagan SE, Clauin S, Bellanne-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, Ellard S 2009 Update of mutations in the genes encoding the pancreatic | -cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat 30:170-180

12. Suchi M, MacMullen CM, Thornton PS, Adzick NS, Ganguly A, Ruchelli ED, Stanley CA 2006 Molecular and immunohistochemi-cal analyses of the focal form of congenital hyperinsulinism. Mod Pathol 19:122-129

13. Giurgeal, Sempoux C, Bellanne-Chantelot C, Ribeiro M, Hubert L, Boddaert N, Saudubray JM, Robert JJ, Brunelle F, Rahier J, Jaubert F, Nihoul-Fekete C, de Lonlay P 2006 The Knudson's two-hit model and timing of somatic mutation may account for the phenotypic diversity of focal congenital hyperinsulinism. J Clin Endocrinol Metab 91:4118-4123

14. Slack JM 1995 Developmental biology of the pancreas. Development 121:1569-1580

15. Hebrok M, Kim SK, St Jacques B, McMahon AP, Melton DA 2000 Regulation of pancreas development by hedgehog signaling. Development 127:4905-4913

Endocrine Society®

You can post your CVV post an open position or look for your next career opportunity in the targeted Career Services site.